Key Highlights

  • RAPP shares traded up 2.55% to $29.33, versus a prior close of $28.60.
  • RAP-219 showed a 3.1-point placebo-adjusted YMRS improvement at Week 3 with p=0.045.
  • All treatment-emergent adverse events were mild or moderate.
  • Phase 3 trials are expected to begin in the second half of 2027.
  • Cash of $436.1 million is expected to fund operations into the second half of 2029.

RAP-219 Meets Its Primary Endpoint in Bipolar Mania

Rapport Therapeutics (NASDAQ:RAPP) shares traded up 2.55% to $29.33 after the company reported positive topline Phase 2 results for RAP-219 in acute bipolar mania. The trial enrolled 253 adults and met its primary endpoint, a 3.1-point placebo-adjusted improvement in the Young Mania Rating Scale total score at Week 3, with a p-value of 0.045.

Patients on RAP-219 had a 15.4-point mean reduction, versus 12.3 points on placebo. The secondary measure of mania severity also reached significance, with a 0.4-point improvement and a p-value of 0.024.

Why the Reaction Was Muted

The stock moved sharply early in the session before settling modestly higher. Investors weighed a result below the roughly 4-point effect the company had targeted, a higher discontinuation rate of 24.6% against 11.8% on placebo and a thin statistical margin.

On the supportive side, William Blair called the data within the range of approved bipolar therapies, and Wells Fargo maintains a Buy rating with a $51 target. The company said tolerability looked favorable, with no severe adverse events during treatment.

Cash Runway and the Wider Pipeline

Rapport has about $436.1 million in cash and short-term investments, which it expects to fund operations into the second half of 2029. Shares trade against a 52-week range of $23.75 to $52.93, with a market capitalization of about $1.41 billion. RAP-219 is also in Phase 3 development for focal onset seizures.

FDA Meeting in the First Quarter of 2027 Is the Next Marker

Rapport plans to meet the FDA in the first quarter of 2027 to discuss the data and the design of registrational trials, with two Phase 3 studies expected to start in the second half of 2027. Initial long-term data in focal onset seizures are also expected in the fourth quarter of 2026.